Department of Pharmacology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung, Indonesia.
Trop Med Int Health. 2010 Nov;15(11):1289-99. doi: 10.1111/j.1365-3156.2010.02625.x.
To review the current knowledge about tuberculosis (TB) and diabetes, assessing the implication of the global increase of diabetes for TB control and patient care.
Systematic literature review.
Using public databases, it can be estimated that 12.6% (95% CI 9.2-17.3%) of new TB cases in the 10 countries with the highest TB burden will be attributable to TB in 2030, a relative increase of 25.5% compared to 2010. Diabetes is associated with a higher age and body weight among patients with TB, but probably not with a specific clinical presentation of TB. Rifampicin hampers glycemic control by increasing the metabolism of most oral antidiabetic drugs, while diabetes patients may have lower concentrations of anti-TB drugs. This might be one factor contributing to higher TB treatment failure rates.
The global epidemic of diabetes has implications for control and treatment of TB. Prospective studies are needed to improve prevention, early detection and treatment of concomitant diabetes and TB, especially in developing countries.
回顾结核病（TB）和糖尿病的现有知识，评估全球糖尿病发病率的增加对结核病控制和患者护理的影响。
系统文献回顾。
利用公共数据库，可以估计在结核病负担最重的 10 个国家中，2030 年将有 12.6%（95%CI9.2-17.3%）的新结核病病例归因于结核病，与 2010 年相比，相对增加了 25.5%。糖尿病与结核病患者的年龄和体重较高有关，但可能与结核病的特定临床表现无关。利福平通过增加大多数口服抗糖尿病药物的代谢来干扰血糖控制，而糖尿病患者的抗结核药物浓度可能较低。这可能是导致结核病治疗失败率较高的一个因素。
糖尿病的全球流行对结核病的控制和治疗有影响。需要前瞻性研究来改善糖尿病和结核病的共同预防、早期发现和治疗，特别是在发展中国家。
